Therapies Targeting Stroke Recovery

被引:16
|
作者
Richard, Lorie G. [1 ]
Cramer, Steven C. [2 ,3 ]
机构
[1] Univ Utah, Dept Occupat & Recreat Therapies, Salt Lake City, UT USA
[2] Univ Calif Los Angeles, Dept Neurol, 710 Westwood Plaza,Reed C239, Los Angeles, CA 90024 USA
[3] Calif Rehabil Inst, Los Angeles, CA USA
关键词
clinical trial; depression; phenotype; precision medicine; rehabilitation; stroke; therapeutics; ISCHEMIC-STROKE; REHABILITATION; DEPRESSION; STATEMENT; INJURY; CARE;
D O I
10.1161/STROKEAHA.122.041729
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Stroke recovery therapeutics include many classes of intervention and numerous treatment targets. Stroke is a very heterogeneous disease. As such, stroke recovery therapeutics benefit from a personalized medicine approach that considers intersubject differences, such as in infarct location or stroke severity, when assigning treatment. Prediction of treatment responders can be improved by incorporating biological measures, such as neural injury and neural function, as the bedside behavioral phenotype has an incomplete relationship with the biological events underlying stroke recovery. Another ramification of high variability between patients is the need to examine effects of restorative therapies in relation to dose, time poststroke, and stroke severity in clinical trials. For example, enrollment across a wide time interval poststroke or in a population with a very broad range of deficits means high variance across patients in the biological state of the brain. The doses of rehabilitation therapy being studied are often low; it takes substantial practice to acquire a skill in the healthy brain; this is more, not less, pronounced after a stroke. Recognition and treatment of poststroke depression represents a major unmet need. These points are considered in the context of a review of recent advances in stroke recovery therapeutics.
引用
收藏
页码:265 / 269
页数:5
相关论文
共 50 条
  • [41] Targeting neuroplasticity to improve motor recovery after stroke: an artificial neural network model
    Norman, Sumner L.
    Wolpaw, Jonathan R.
    Reinkensmeyer, David J.
    BRAIN COMMUNICATIONS, 2022, 4 (06)
  • [42] Novel Therapies Targeting Endometriosis
    Hugh S. Taylor
    Kevin G. Osteen
    Kaylon L. Bruner-Tran
    Charles J. Lockwood
    Graciela Krikun
    Anna Sokalska
    Antoni J. Duleba
    Reproductive Sciences, 2011, 18 : 814 - 823
  • [43] Gene therapies targeting the liver
    Cozmescu, Andrei Claudiu
    Counsell, John
    Gissen, Paul
    JOURNAL OF HEPATOLOGY, 2021, 74 (01) : 235 - 236
  • [44] Novel Therapies Targeting Endometriosis
    Taylor, Hugh S.
    Osteen, Kevin G.
    Bruner-Tran, Kaylon L.
    Lockwood, Charles J.
    Krikun, Graciela
    Sokalska, Anna
    Duleba, Antoni J.
    REPRODUCTIVE SCIENCES, 2011, 18 (09) : 814 - 823
  • [45] Targeting Pericytes for Angiogenic Therapies
    Kelly-Goss, Molly R.
    Sweat, Rick S.
    Stapor, Peter C.
    Peirce, Shayn M.
    Murfee, Walter L.
    MICROCIRCULATION, 2014, 21 (04) : 345 - 357
  • [46] Targeting ubiquitination for cancer therapies
    Morrow, John Kenneth
    Lin, Hui-Kuan
    Sun, Shao-Cong
    Zhang, Shuxing
    FUTURE MEDICINAL CHEMISTRY, 2015, 7 (17) : 2333 - 2350
  • [47] Apoptosis-targeting therapies
    Melnikova, I
    Golden, J
    NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (11) : 905 - 906
  • [48] Targeting psoriasis with new therapies
    Prohic, A.
    Helppikangas, H.
    Muhovic, J.
    MEDICINSKI GLASNIK, 2007, 4 (02) : 56 - 62
  • [49] Gene targeting therapies for LBSL
    Nemeth, Christina
    Ratajczak, Adam
    Amanat, Manouchehr
    Guang, Shiqi
    Ying, Mingyao
    Fatemi, Ali
    JOURNAL OF NEUROCHEMISTRY, 2023, 166 : 101 - 101
  • [50] Apoptosis-targeting therapies
    Irena Melnikova
    James Golden
    Nature Reviews Drug Discovery, 2004, 3 : 905 - 906